The Setup: A $1.1B Rare Disease Machine at 8x Earnings
ANI Pharmaceuticals (NASDAQ: ANIP) trades at $74 with a forward P/E of 8.4x. The company just guided to $1.06-$1.12 billion in 2026 revenue — beating analyst consensus by roughly 10% — and its lead drug, Cortrophin Gel, grew 76% last year with another 55-65% growth baked into 2026 guidance. Then yesterday, Trump signed a 100% tariff on imported branded pharmaceuticals effective July 31, 2026.
Most investors still haven’t looked twice at this name.
What ANI Pharmaceuticals Actually Does
ANI isn’t a drug developer burning cash on Phase 2 trials. It’s a commercial-stage specialty pharma company running two lanes: a rare disease franchise anchored by Cortrophin Gel, and a generics business that throws off steady cash.
Cortrophin Gel is a purified repository corticotropin injection — a synthetic hormone that modulates inflammation across multiple pathways. It treats conditions where conventional steroids stop working or create unacceptable side effects: rheumatology, nephrology, pulmonology, ophthalmology, neurology. The drug competes primarily with Keenova Therapeutics’ Acthar Gel, the only other product in its class.
The generics business is simpler: ANI manufactures roughly 180 generic products across tablets, capsules, and oral solutions from its U.S. facilities in Baudette, Minnesota and Oakville, Ontario.
In 2025, ANI posted approximately $883 million in total revenue. Rare Disease and Brands contributed $484 million (54.8%); Generics filled the other 45.2%. Revenue is overwhelmingly domestic — $852 million U.S. versus $31 million international.
Compare this to another specialty pharma play we covered recently: Catalyst Pharmaceuticals (CPRX), which similarly beat earnings massively while the market shrugged. There’s a pattern of the market undervaluing small-cap specialty pharma with dominant drugs in niche markets.
Cortrophin Gel: 76% Growth Last Year, 60% More Guided This Year
Cortrophin Gel delivered $347.8 million in 2025 revenue, up 76% year-over-year. This isn’t a one-quarter spike. ANI acquired the product from Novartis, rebuilt the regulatory file, got FDA approval in 2021, and has been gaining share across specialty medicine ever since.
The 2026 Cortrophin guidance is $540-$575 million — which implies that single drug will represent roughly 60% of total company revenue. To hit that number, ANI is deploying a roughly 90-person dedicated sales force targeting acute gouty arthritis flares starting mid-2026. Management called the gout opportunity “large and relatively untapped” because Cortrophin Gel resolves acute flares faster than oral colchicine for patients who can’t tolerate alternatives.
In March 2025, the FDA approved a prefilled syringe formulation of Cortrophin. Launched in Q2 2025, it drove record new patient starts across all five specialty segments by making self-administration easier. Small product iteration, real commercial impact.
One timing note: Q1 2026 Cortrophin is guided to represent only 13-14% of full-year sales due to insurance reverifications and winter disruptions. That’s typical seasonality, not a structural problem. The gout team deployment in mid-2026 is where sequential acceleration happens.
The Tariff Catalyst Nobody Is Pricing In
April 2, 2026: Trump signed a presidential proclamation imposing 100% tariffs on imported patented pharmaceuticals and APIs under Section 232 of the Trade Expansion Act. Effective date: July 31, 2026.
The proclamation cited national security: 53% of patented drugs distributed in the U.S. are manufactured outside the country; only 15% of APIs are made domestically.
Jefferies analyst Alok Dalal offered the clearest read on what this means for different parts of the market: generic drugs are likely exempt because imposing 100% tariffs on thin-margin generics risks triggering drug shortages. Foreign branded drug companies that haven’t reached deals with the White House face the full 100%; countries with negotiated agreements (South Korea, EU) face a capped rate around 15%.
Where does this leave ANI? Well-positioned on both fronts. Cortrophin Gel is manufactured domestically — no import tariff exposure, no supply chain risk. The generics business is expected to remain tariff-exempt. And any foreign competitor trying to enter the U.S. specialty corticotropin market now faces a massive structural cost disadvantage if their manufacturing is offshore.
This isn’t a direct earnings catalyst today. But it meaningfully raises the moat around domestic specialty drug manufacturers — and ANI is one of them.
The Numbers
Full 2026 guidance from management:
– Total net revenue: $1.06-$1.12 billion
– Cortrophin Gel revenue: $540-$575 million
– Adjusted EBITDA: $275-$290 million
– Adjusted EPS: $8.83-$9.34
– Adjusted gross margin: 59.3-60.3%
At ANIP’s $74.21 price:
– Forward P/E: 8.4x (on ~$9.09 EPS midpoint)
– Forward P/S: ~1.5x (on ~$1.09B revenue midpoint)
– EV/EBITDA: ~7x ($1.99B enterprise value vs. $282.5M EBITDA midpoint)
Q4 2025 standalone: $247.1 million revenue, up 29.6% year-over-year, beat analyst estimates by 6.9%. Adjusted EPS $2.33. The company also reported $294.72 million in cash, ROE of 16.16%, and free cash flow of $119.42 million trailing twelve months.
The 52-week range tells a story: $53.35 to $98.81. ANIP is sitting at $74, in the lower half of its range, despite posting record revenue and guiding to significant acceleration. Something got repriced that probably shouldn’t have.
Bull Case
Three things need to go right.
The gout launch executes. The 90-person dedicated gout sales force is a meaningful commercial investment. If acute gouty arthritis becomes a real fourth pillar for Cortrophin Gel alongside rheumatology, nephrology, and pulmonology, then the $540-575M revenue guide starts looking conservative. Every commercial expansion ANI has tried with Cortrophin has outperformed initial modeling.
Retina recovers. The ophthalmology franchise (ILUVIEN for diabetic macular edema, YUTIQ for posterior uveitis) went through a 2025 reset due to reimbursement changes. New clinical data from the NEW DAY trial for ILUVIEN is expected in 2026. If that data is strong, retina goes from a headwind to a contribution, which pushes EPS toward the high end of $9.34.
Multiple rerates. A specialty pharma company with $9+ in EPS, 59%+ gross margins, 16% ROE, and its primary drug still in early market penetration simply should not trade at 8x earnings. The discount exists because the market doesn’t yet trust the Cortrophin scale-up. When Q3 2026 shows the gout team delivering, you get both the EPS beat and the multiple expansion simultaneously.
HC Wainwright has a $121 price target. Guggenheim recently raised its target to $124. Both imply 65%+ upside from current prices.
The parallel to other undervalued small-caps is worth noting — we’ve written about similar setups in different sectors, from Marex Group at 11x earnings to small-cap defense plays the market hasn’t repriced yet. The pattern is consistent: the market discounts quality businesses until the evidence is undeniable.
Bear Case
Payer risk is the primary threat. Cortrophin Gel is expensive. If a major PBM decides to restrict access or require step therapy, ANI’s revenue growth stops faster than most models assume. Acthar Gel competition means patients have an alternative. Payer pushback on high-cost specialty steroids has happened before in this market.
The debt load is real. Total debt/equity sits at 116% — not catastrophic, but it means the company has limited flexibility if the Cortrophin ramp disappoints. A softer quarter forces cuts rather than investment.
Retina risk cuts both ways. If the NEW DAY trial data disappoints and the retina franchise stays in reset mode into 2027, then the generics engine has to carry more weight in a notoriously price-competitive market.
And the tariff catalyst is far from guaranteed to stick. Pharmaceutical lobbying is relentless. Executive actions get modified. The 100% tariff structure announced yesterday could look materially different by the time July 31 arrives.
Argus rates ANIP a Hold with a $72 price target — they see the balance sheet leverage and execution dependency on Cortrophin as sufficient reasons to stay neutral.
Verdict
ANIP at $74 is genuinely cheap for what it is. A $1B+ revenue specialty pharma business, growing at 25%+ annually, with 59% gross margins, a domestically manufactured lead product, and an expanding gout indication — at 8.4x forward earnings.
The tariff backdrop adds asymmetric upside without changing today’s model. Being on the right side of a national security policy that penalizes foreign pharmaceutical manufacturing is a free option.
The risk scenario is Cortrophin growth disappointing materially — which would require payer restrictions that haven’t emerged despite multiple years of commercial scaling. That’s possible but it’s not the base case.
Compelling below $80. Would get aggressive below $68 if the market gives us another dip on Q1 seasonality noise.
This is not financial advice. Do your own research before making investment decisions. The author holds no position in ANIP.